Hegseth announces new policy to test troops for low testosterone and offer them hormone replacement therapy

Key Points:

• Pentagon official Peter Hegseth announced a new initiative to facilitate testosterone replacement therapy for troops, aiming to keep them "strong, resilient and capable" amid the demands of modern battlefields, though the Pentagon did not specify underlying research or if female troops would receive similar hormone therapies.
• The move aligns with broader Trump administration efforts, including Health Secretary Robert F. Kennedy Jr.'s push to ease FDA restrictions on testosterone prescriptions, despite ongoing medical debates about appropriate diagnosis and treatment of low testosterone.
• Testosterone use among special operations forces, particularly Navy SEALs, has faced scrutiny following a recruit's death in 2022 linked to hormone use, prompting the Navy to implement drug testing for testosterone-related substances.
• Medical experts caution against widespread testosterone testing due to natural hormone fluctuations and recommend therapy only for men with documented low levels and symptoms; recent studies suggest benefits for sexual function but limited impact on other health measures.
• Critics, including Rep. Chrissy Houlahan, question Hegseth's motivations and highlight his controversial stance on women in combat roles, noting his history of opposing female military leadership and policies favoring "highest male standards."